Breeze Holdings Acquisition Corp. announced that its stockholders voted to approve the business combination with YD Biopharma Limited, a Taiwan-based biopharmaceutical company.
The approval was made at a special meeting of stockholders held on August 14, 2025, with a significant majority in favor of the Business Combination Proposal.
Upon closing, the combined company will operate as YD Bio Limited and is expected to trade on Nasdaq under the ticker symbol "YDES."
Approval of Business Combination
Breeze Holdings Acquisition Corp.'s stockholders voted in favor of the business combination with YD Biopharma Limited.
Trading on Nasdaq
The combined company, YD Bio Limited, is set to trade on Nasdaq under the ticker symbol "YDES."
Expected Closing Date
The closing of the transaction is anticipated to occur within the next two weeks, subject to customary closing conditions.
- The approval by Breeze Holdings Acquisition Corp.'s stockholders indicates confidence in the strategic alignment with YD Biopharma Limited.
- The trading on Nasdaq with the new ticker symbol highlights the company's transition to a publicly traded entity with increased visibility.
The approval of the business combination and the upcoming trading on Nasdaq mark significant milestones for Breeze Holdings Acquisition Corp. and YD Biopharma Limited, signaling a new chapter of growth and opportunities in the biopharmaceutical industry.